Upload
adanna
View
47
Download
0
Tags:
Embed Size (px)
DESCRIPTION
Combining neuropsychology and genetics in the study of mood disorders. Daniel Smith MRCPsych Division of Psychiatry, University of Edinburgh Specialist Registrar in Psychiatry, Southern General Hospital, Glasgow. [email protected]. Overview – three reports:. - PowerPoint PPT Presentation
Citation preview
Combining neuropsychology and genetics in the study of mood disorders
Daniel Smith MRCPsych
Division of Psychiatry, University of Edinburgh
Specialist Registrar in Psychiatry, Southern General Hospital, Glasgow.
Overview – three reports:
• Recurrent MDD patients versus controls
• ‘pure unipolar’ patients versus bipolar-spectrum disorder (BSD) patients
• MDD patients with BDNF gene abnormality versus patients without BDNF gene abnormality
Recurrent early-onset major depressive disorder (RE-MDD)
• Defined as 2 or more episodes of MDD before age 22
• Is highly morbid (Zubenko et al, 2001)
• Is probably a ‘more genetic’ sub-group of depression (Maher et al, 2002)
• Carries a high risk of progression to bipolar disorder (Smith et al, in press)
Depression in young adults
Clinical characteristics
Genetic risk factors
‘endophenotypes’
environmental factors
Personality traits
Neurocognitive impairment
Drugs and alcohol
Life events
Early adversity
Bipolar-spectrum disorders
BDNF
Outline of study
234 consecutive referrals in 12 month recruitment period
90 with current depression and at least one previous episode of depression
87 agreed to participate
Initial assessment:SCID-1 diagnostic assessment; symptom severity; quality of life; family history; life
events; drug and alcohol use; DSH and suicidal behaviour; blood sample for DNA
After 3 months on treatment:Symptom severity; Quality of life
Neuropsychology assessmentPersonality dimensions assessment
Neuropsychological impairment in mood disorders
• Affected by clinical sub-type
• Lack of study of homogeneous groups
• Depends on stage of illness
• ‘endophenotype’ theory versus ‘scarring’ effect
• May reflect structural brain abnormalities
Cognitive deficits in depression and bipolar disorder across mood states
Cognitive domain
Cognitive task
Euthymic state
Depressed state
Manic state
Attention Continuous performance task
(CPT)
Trail-making Test, part A (TMT-A)
Digit Symbol
Substitution Test (DSST)
No
Yes
Yes
Yes
Yes
Yes
Yes
No ?
Executive function
Wisconsin Card Sort Test (WCST)
Stroop test
Trail-making Test,
part B (TMT-B)
Yes
Yes
Yes
? ?
Yes
Yes
Yes
?
Verbal memory
California Verbal learning Test
(CVLT)
Yes
Yes
Yes
Brain regions implicated in mood disorders
• Prefrontal cortex• Dorsolateral:
– Verbal memory– Attention– Executive function
• Anterior cingulate:– Executive function
• Hippocampus– Verbal memory
Neuropsychological battery in this study
• Assessed for clinical recovery (euthymia) using HRSD (<8)
• Estimate of intellectual functioning:• National Adult Reading Test (NART)• Number of years in full-time education• Block design sub-section score of the WAIS-R
• Verbal memory:• California Verbal Learning Test (CVLT)
• Executive function:• Stroop Colour Word Test• Brixton spatial anticipation test• Trail-making test A and B
Patients and controls were well matched
Characteristic MDD patients (n=63)
Mean (SD)
Controls (n=33)
Mean (SD)
Significance test and p-value
Age (years)
Gender ratio (F:M)
21.7 (2.25)
43:20
22.2 (2.29)
19:14
t=-1.22, df=94, p<0.03
X2=1.08, df=2, p<0.30
NART IQ Block design (WAIS) Education (years)
HRSD score
117.5 (3.56)
44.9 (5.96)
16.7 (1.59)
2.6 (1.95)
115.9 (3.69)
45.8 (3.13)
17.3 (1.40)
1.9 (0.93)
t=2.02, df=94, p<0.05
t=-0.85, df=94, p<0.40
t=-1.93, df=94, p<0.06
t=1.71, df=94, p<0.09
Current medications:Antidepressants only, n (%)Mood stabilisers only, n (%)Both, n (%)Neither, n (%)
48 (76.2)8 (12.7)6 (9.5)1 (1.4)
0000
------------
Results (1): MDD patients versus controls
Verbal learning and memory (CVLT)
MDD patients(n=63)
Mean (SD)
Controls(n=33)
Mean (SD)
Significance test
Trial 1 Trials 1 to 5 total Short delay recall Long delay recall
Delayed recognition minus false positives
7.0 (1.85)
55.2 (8.42)
12.5 (2.69)
12.6 (2.64)
14.7 (1.49)
7.7 (1.79)
60.7 (6.57)
13.5 (1.91)
13.9 (1.98)
15.2 (1.00)
t=-1.85, df=94, p<0.07
t=-3.30, df=94,
p<0.001
t=-1.77, df=94, p<0.08
t=-2.47, df=94,
p<0.01
t=-1.4, df=94, p<0.16
Results (2): MDD patients versus controls
Attention and executive function
MDD patients(n=63)
Mean (SD)
Controls(n=33)
Mean (SD)
Significance test
Stroop colour trial correct Stroop colour word trial correct Brixton test Trail-making Part A (s) Trail-making Part B (s)
111.6 (0.63)
109.1 (2.58)
6.8 (1.67)
30.3 (8.0)
58.6 (16.4)
111.7 (0.47)
110.4 (1.17)
7.4 (1.62)
29.0 (35.3)
45.3 (10.9)
t=-0.50, df=94, p<0.62
t=-2.77, df=94,
p<0.01
t=-1.78, df=94, p<0.08
t=0.28, df=94,
p<0.78
t=4.27, df=94, p<0.0001
Conclusion: MDD patients versus controls
• Subtle impairments in:
– Verbal memory– CVLT trials 1 to 5 total
– Executive function– Stroop Colour Word errors– Trail-making Part B
Young people with recurrent depression are at high risk of progression to bipolar disorder
• 19% of out-patient depressed adolescents develop bipolar disorder 1
• 47% of young adults hospitalised with depression develop bipolar disorder 2
• Bipolar illnesses tend begin with an episode of depression rather than mania 3
• Most people with bipolar disorder date the onset of their illness to adolescence 3
1. Rao et al., 1995, J. Am. Acad. Child & Adol. Psych., 34, 566-578.
2. Goldberg et al., 2001, Am. J. Psych., 158, 1265-1270.
3. Lisj et al., 1994, J. Aff. Disord., 31, 281-294.
Diagnostic criteria for bipolar spectrum disorder (BSD)
A at least one major depressive episode
B no spontaneous DSM-IV hypomanic or manic episodes
C either of the following plus two from D or both plus one from D:
• First degree relative with bipolar disorder
• Antidepressant-induced mania or hypomania
D if none from C, at least six of the following:
• Hyperthymic personality• > 3 depressive episodes• Brief major depressive episodes (< 3 months)• Atypical depressive symptoms• Psychotic major depressive episodes• Early age of onset (< 25)• Postpartum depression• Antidepressant ‘wear-off’ (acute but not prophylactic response)• Lack of response to > 2 antidepressant trials
Ghaemi, S.N., Ko, J.Y., Goodwin, F.K., Cade's Disease and beyond: misdiagnosis, antidepressant use and a proposed definition for bipolar spectrum disorder. Canadian Journal of Psychiatry, 2002. 47(2): p. 125-134.
Diagnoses (using diagnostic criteria for bipolar spectrum disorder, BSD)
0
10
20
30
40
50
60
70
80
90
DSM-IV bipolar disorder DSM-IV MDD
% subjects
0
10
20
30
40
50
60
70
80
90
DSM-IV bipolar disorder DSM-IV MDD
% subjects
BSD
unipolars
Smith, D.J., Harrison, N., Muir, W., Blackwood, D.H.R., High prevalence of bipolar spectrum disorders in young adults with recurrent depression: toward a novel diagnostic framework. Journal of Affective Disorders., in press.
‘pure unipolar’ patients versus BSD patients: CVLT, trials 1-5
46
48
50
52
54
56
58
60
62
Bipolar spectrum disorder(n=21)
'pure unipolar' (n=42)
Controls (n=33)
DSM-IV MDD (n=63)
Controls > DSM-IV MDD; p<0.001
Controls > BSD; p<0.001
Pure unipolar > BSD; p<0.06
Mean score
CVLT trials 1-5
‘pure unipolar’ patients versus BSD patients: Trail-making Test
0
10
20
30
40
50
60
70
TMA TMB
Bipolar spectrum disorder(n=21)
'pure unipolar' (n=42)
Controls (n=33)
BSD > Controls; p<0.001
BSD > ‘pure unipolar’; p<0.03
‘pure unipolar’ > Controls; p<0.01
N.S.
seconds
‘pure unipolar’ patients versus BSD patients: Stroop Colour Word Test
0
0.5
1
1.5
2
2.5
3
3.5
4
Stroop Colour Stroop Colour-Word
Bipolar spectrum disorder(n=21)
'pure unipolar' (n=42)
Controls (n=33)
errors
BSD > Controls; p<0.002
BSD > ‘pure unipolar’; N.S.
MDD > Controls; N.S.
Conclusion: ‘pure MDD’ patients versus BSD patients
• BSD patients appear to have more impairment in:– Verbal memory (CVLT, trials 1-5)– Executive function (Trail-making test, part B)
• Indirect support for the validity of the proposed diagnostic criteria for BSD
Manji, H. (2003) American Journal of Psychiatry 160 (1) 24.
Intracellular signalling pathways mediating cellular resilience and neuroplasticity
Brain-derived neurotrophic factor (BDNF)
• Is a neurotrophin found in the neocortex, hippocampus and amygdala 1
• Modulates hippocampal plasticity and hippocampal-dependant memory 1
• Is upregulated by antidepressant therapy 2
• Is associated with bipolar affective disorder 3,4
1. Lu & Gottschalk (2000) Progress in Brain Research, 128:231-241
2. Reid & Stewart (2001) British Journal of Psychiatry, 178:299-303
3. Neves-Pereira et al. (2002) American Journal of Human Genetics, 71:651-655
4. Sklar et al. (2002) Molecular Psychiatry, 7:579-593
The Val66Met polymorphism of BDNF
– Single nucleotide polymorphism at nucleotide 196 (G/A; dbSNP number rs6265) produces an amino acid substitution at codon 66 (Val66Met)
– Approximate frequencies in human controls:• 68% val/val• 27% val/met• 5% met/met
The BDNF val66met polymorphism affects activity-dependant secretion of BDNF and human memory and hippocampal function.
Egan et al., (2003) Cell, 112;257-269.
– met allele associated with:• Poorer episodic memory• Abnormal hippocampal activation on fMRI• Lower hippocampal intracellular N-acetyl
aspartate
– val/met exerts these effects through intracellular trafficking and activity-dependant secretion of BDNF
Bipolar patients carrying the Met allele of the BDNF polymorphism perform worse on the Wisconsin Card Sort Test
Rybakowski et al (2003) Bipolar Disorders, 5(6):468-472
Val/Val(n=44)
Mean (SD)
Val/Met(n=9)
Mean (SD)
Significance test
Perseverative errors 10.5 (5.0) 17.0 (15.6) P < 0.03
Non-perseverative errors 9.8 (5.5) 15.9 (15.2) P < 0.04
Is this polymorphism associated with cognitive impairment in young adults with recurrent depression?
Genotype frequencies in this sample of MDD patients (n=40)
• 24 patients were val/val
• 15 were val/met
= 16 with at least one met allele
• 1 was met/met
Val/Val genotype
N=24
Mean (SD)
Val/Met or Met/MetgenotypeN=16
Mean (SD)
Significance test
Age 21.7 (2.28) 22.1 (1.88) N.S.
F:M ratio 2:1 3:1 N.S.
MADRS score 2.92 (2.02) 3.06 (1.78) N.S.
Premorbid IQ:Number of years of full-time education
NART error scoreFull-scale IQ
Block design WAIS
16.8 (1.69)
10.5 (2.17)117.7 (2.71)
44.9 (6.87)
16.9 (1.50)
10.1 (2.60)118.1 (3.30)
46.9 (3.63)
N.S.
N.S.N.S.
N.S.
Comparison groups were well-matched:
Val/Val genotype
N=24
Mean (SD)
Val/Met or Met/Met genotypeN=16
Mean (SD)
Significance test
CVLT (trials 1-5) 55.3 (8.8) 55.1 (8.1) N.S.
Brixton raw score 13.0 (4.15) 12.5 (4.00) N.S.
Trailmaking ATrailmaking BB-A
28.8 (6.01)53.1 (9.05)24.3 (8.49)
29.6 (7.47)65.3 (21.1)37.8 (19.7)
N.S.P < 0.04P < 0.04
Stroop C errorsStroop CW errors
0.21 (0.41)2.17 (2.06)
0.50 (0.63)4.56 (3.54)
N.S.P < 0.02
Neuropsychological assessment:
Conclusions re: BDNF
• Neurocognitive abnormalities associated with this polymorphism of BDNF are not limited to hippocampal impairment
• In recurrent, early-onset major depression the val66met BDNF polymorphism is associated with impaired frontal executive function but not with hippocampal impairment
• Is this a reflection of a bipolar diathesis in these young recurrently depressed patients?
Final Summary
• Subtle frontal and hippocampal impairments in euthymic young adults with recurrent depression compared to controls– Is this an endophenotypic characteristic?
• Neuropsychological support for the proposed diagnostic criteria for bipolar-spectrum disorder (BSD)
• Possible to demonstrate that abnormalities of genes implicated in cognitive function and risk for mood disorder are associated with cognitive deficits in recovered patients
Acknowledgments
• Funded by the Kate Hodgson Memorial Fellowship, University of Edinburgh and by the Health Foundation UK
• Psychiatric genetics research group in Edinburgh:– Douglas Blackwood– Walter Muir– David Porteous– Maura Walker– Margaret van Beck
• Genotypying lab at the University of Dundee:– Murray Wilkie– Gillian Smith– Roland Wolf
• Thanks to general practitioners at the University Health Service in Bristo Square, Edinburgh and community mental health team at Ballendon House, Edinburgh